HC Wainwright Issues Positive Outlook for ELDN Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Analysts at HC Wainwright increased their Q3 2025 earnings per share estimates for Eledon Pharmaceuticals in a research note issued on Tuesday, September 2nd. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.18) per share for the quarter, up from their prior estimate of ($0.31). HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Eledon Pharmaceuticals’ Q4 2025 earnings at ($0.18) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.30) EPS and FY2026 earnings at ($1.31) EPS.

Other equities research analysts also recently issued research reports about the company. Craig Hallum started coverage on Eledon Pharmaceuticals in a research report on Friday, July 25th. They set a “buy” rating and a $12.00 price target for the company. Wall Street Zen downgraded Eledon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, June 6th. Finally, Zacks Research downgraded Eledon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 18th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.00.

Eledon Pharmaceuticals Trading Up 3.8%

ELDN stock opened at $2.71 on Thursday. The stock has a 50-day moving average price of $3.05 and a two-hundred day moving average price of $3.17. Eledon Pharmaceuticals has a 12-month low of $2.38 and a 12-month high of $5.54. The company has a market cap of $162.27 million, a PE ratio of -2.32 and a beta of -0.12.

Eledon Pharmaceuticals (NASDAQ:ELDN) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.10.

Institutional Investors Weigh In On Eledon Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Ground Swell Capital LLC purchased a new stake in shares of Eledon Pharmaceuticals in the second quarter worth about $31,000. Tower Research Capital LLC TRC lifted its stake in shares of Eledon Pharmaceuticals by 418.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company’s stock worth $33,000 after acquiring an additional 6,412 shares in the last quarter. ProShare Advisors LLC acquired a new position in shares of Eledon Pharmaceuticals in the second quarter worth about $33,000. CW Advisors LLC acquired a new position in shares of Eledon Pharmaceuticals in the first quarter worth about $34,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Eledon Pharmaceuticals in the second quarter worth about $37,000. Hedge funds and other institutional investors own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).